Lutetium

Scientific Overview: PSMA-targeted peptide radioligand therapy; FDA approved 2022 for mCRPC. PSMA RLT — transformed mCRPC treatment; improved OS in TheraP/VISION

Mechanism of Action: PSMA-Targeted Radiotherapy (Lu-177)

Purity: ≥99%  |  Molecular Formula: C49H74LuN9O15

For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.